

DATA SHEET

REAGENT	SARS-CoV-2 isolate - Mu (B.1.621 lineage) - infectious
REPOSITORY REFERENCE	101034
LOT NUMBER	28092021
DESCRIPTION	Passage 3Mu isolate grown in the Vero/hSLAM cell line. Originally isolated and passaged in the Vero/hSLAM cell line by UKHSA. Mycoplasma undetectable, sterility checked. TCID50/mL in VeroE6: 1.36 x 1e7
PROVIDED	1mL of clarified culture supernatant
SEQUENCE	

In blue are Mu defining mutations (<https://outbreak.info>). All mutations are present except ORF3a 256-257 deletion where a **frameshift is detected**. Details about the sequencing protocol is available on request.

Position (NC_045512.2)	Ref	Alt	Proportion	Gene	HGVSp
241	C	T	0.9989	CHR_START-ORF1ab	N/A
639	A	G	0.9827	ORF1ab	p.Lys125Arg
910	G	A	0.0107	ORF1ab	p.Leu215Leu
1685	G	T	0.9988	ORF1ab	p.Ala474Ser
2433	C	T	0.9990	ORF1ab	p.Ser723Phe
3037	C	T	0.9990	ORF1ab	p.Phe924Phe
3428	A	G	0.9997	ORF1ab	p.Thr1055Ala
4456	C	T	0.0123	ORF1ab	p.Ala1397Ala
4684	T	C	0.9994	ORF1ab	p.Ala1473Ala
4878	C	T	0.9994	ORF1ab	p.Thr1538Ile
5497	C	T	0.9987	ORF1ab	p.Cys1744Cys
6037	C	T	0.9988	ORF1ab	p.Ser1924Ser
9502	C	T	0.0121	ORF1ab	p.Ala3079Ala
10029	C	T	0.9984	ORF1ab	p.Thr3255Ile
11451	A	G	0.9992	ORF1ab	p.Gln3729Arg
12036	C	T	0.0139	ORF1ab	p.Ala3924Val
13057	A	T	0.9996	ORF1ab	p.Ser4264Ser
14408	C	T	0.9993	ORF1ab	p.Pro4715Leu
16751	C	A	0.9995	ORF1ab	p.Pro5496His
17000	C	T	0.9882	ORF1ab	p.Thr5579Ile
17491	C	T	0.9995	ORF1ab	p.Pro5743Ser
18412	G	T	0.9991	ORF1ab	p.Val6050Phe
18877	C	T	0.9995	ORF1ab	p.Leu6205Leu

User Ref: 101034	Version: 1.0	Version Date: 07/02/2022
Latest version of document available at: Q-DOCS		Date Printed: 17/02/2022 16:13
Document ID: 9232	Page 1 of 3	Issue Status: Published

Position (NC_045512.2)	Ref	Alt	Proportion	Gene	HGVSp
19035	T	C	0.9991	ORF1ab	p.Ile6257Ile
20148	C	T	0.9994	ORF1ab	p.Phe6628Phe
21364	C	T	0.0140	ORF1ab	p.Pro7034Ser
21846	C	T	0.9990	S	p.Thr95Ile
21990	T	TTAC	0.8526	S	p.Val143_Tyr144insThr
21993	A	C	0.9974	S	p.Tyr144Ser
21995	T	A	0.9973	S	p.Tyr145Asn
22599	G	A	0.9991	S	p.Arg346Lys
22813	G	T	0.9997	S	p.Lys417Asn
23012	G	A	0.9993	S	p.Glu484Lys
23063	A	T	0.9998	S	p.Asn501Tyr
23403	A	G	0.9994	S	p.Asp614Gly
23604	C	A	0.9997	S	p.Pro681His
24410	G	A	0.9991	S	p.Asp950Asn
25563	G	T	0.9994	ORF3a	p.Gln57His
26157	TGTTA	T	0.9627	ORF3a	p.Val256fs
26492	A	T	0.9996	E-M	N/A
27916	G	A	0.9996	ORF8	p.Gly8Glu
27925	C	A	0.9990	ORF8	p.Thr11Lys
28005	C	T	0.9994	ORF8	p.Pro38Ser
28093	C	T	0.9989	ORF8	p.Ser67Phe
28272	A	T	0.9993	ORF8-N	N/A
28378	G	T	0.9987	N	p.Ala35Ala
28887	C	T	0.9993	N	p.Thr205Ile

APPLICATIONS

Infectivity assay, viral growth, neutralisation assay.

DEPOSITOR

Original virus (passage 2) received from Dr Kevin Bewley, UK Health Security Agency, Medical Interventions Group, Porton Down, UK. Passage 3 virus grown and characterised by CFAR.

ACKNOWLEDGMENTS

Acknowledgment for publications should read "The following reagent was obtained from the Centre For AIDS Reagents, NIBSC, UK: Mu (B.1.621 lineage) (#101034), thanks to the contribution of Dr Kevin Bewley".

MATERIAL SAFETY SHEET

Physical properties (at room temperature)	
Physical appearance	Yellow/Pink, liquid
Fire hazard	None
Chemical properties	
Stable	Yes
Corrosive:	No
Hygroscopic	No
Oxidising:	No
Flammable	No
Irritant:	No
Other: Live SARS-CoV-2. It is the responsibility of the end user to seek local biosafety approval for the storage and handling of the material in their workplace	
Handling: CAUTION - This preparation is not for administration to humans or animals in the human food chain. This preparation is hazardous to health. It should be used and discarded according to your own laboratory's safety procedures. Such safety procedures should include the wearing of protective clothing, gloves and use within ACDP3 or higher facility.	
Toxicological properties	
Effects of inhalation:	Likelihood of Coronavirus infection
Effects of ingestion:	Likelihood of Coronavirus infection
Effects of skin absorption:	Not established, avoid contact with skin
Suggested First Aid	
Inhalation	Seek medical advice
Ingestion	Seek medical advice
Contact with eyes	Wash with copious amounts of water. Seek medical advice.
Contact with skin	Wash thoroughly with water.
Action on Spillage and Method of Disposal	
Spillage of contents should be taken up with absorbent material wetted with an appropriate virucidal agent. Rinse area with an appropriate virucidal agent followed by water. Absorbent materials used to treat spillage should be treated as biologically hazardous waste.	